Metraipolis › archive › dc_526053eafbc4
Real-World Outcomes of Combined Carbon-Ion Radiotherapy and Systemic Immunotherapy for Hepatocellular Carcinoma (Atezolizumab Plus Bevacizumab or Durvalumab… — Europe PMC PMID:42513363
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42513363
- DOI
- 10.3390/jcm15145449
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-18T07:57:42.377Z
- SHA-256 of the archived text
14cca96d330e2bcae2bb01be24444e56c9ae6c121b92091ad832bc3db45cf2d5- Stable URL of this page
https://metraipolis.com/documento/dc_526053eafbc4
How to cite
Real-World Outcomes of Combined Carbon-Ion Radiotherapy and Systemic Immunotherapy for Hepatocellular Carcinoma (Atezolizumab Plus Bevacizumab or Durvalumab… — Europe PMC PMID:42513363 — Europe PMC (en), https://europepmc.org/article/MED/42513363 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_526053eafbc4 (Metraipolis archive dc_526053eafbc4, sha256 14cca96d330e2bcae2bb01be24444e56c9ae6c121b92091ad832bc3db45cf2d5)
BibTeX
@misc{dc526053eafbc4,
title = {Real-World Outcomes of Combined Carbon-Ion Radiotherapy and Systemic Immunotherapy for Hepatocellular Carcinoma (Atezolizumab Plus Bevacizumab or Durvalumab… — Europe PMC PMID:42513363},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42513363},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_526053eafbc4; sha256 14cca96d330e2bcae2bb01be24444e56c9ae6c121b92091ad832bc3db45cf2d5},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42513363. Agents can read the archived copy with the MCP tool read_document.